• Publications
  • Influence
Graft-versus-leukemia reactions after bone marrow transplantation.
TLDR
The results explain the efficacy of allogeneic bone marrow transplantation in eradicating leukemia, provide evidence for a role of the immune system in controlling human cancers, and suggest future directions to improve leukemia therapy. Expand
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
TLDR
Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk. Expand
Lenalidomide after stem-cell transplantation for multiple myeloma.
TLDR
Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. Expand
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
TLDR
It is recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily and the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) is confirmed. Expand
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.
TLDR
In multivariate modeling, patient age, race, disease stage, and cytomegalovirus status were as predictive of survival as donor HLA matching, and high-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival. Expand
Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study
TLDR
These data support the use of HLA-matched and one- or two-antigen Hla-mismatched umbilical cord blood in children with acute leukaemia who need transplantation and greater investment in large-scale banking is needed to increase HLA diversity. Expand
Defining the intensity of conditioning regimens: working definitions.
TLDR
This report proposes to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablatives (NMA) Conditioning, based on the duration of cytopenia and on the requirement for stem cell support. Expand
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
TLDR
It is concluded that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD. Expand
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
TLDR
A Markov model constructed to examine 3 transplantation strategies for newly diagnosed MDS found that delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated for low- and intermediate-1-risk patients. Expand
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
TLDR
The validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories. Expand
...
1
2
3
4
5
...